Approval of the drug would be a win for Lilly as it tries to maintain dominance over the GLP-1 market, where it has already overtaken rival company Novo Nordisk, manufacturer of Ozempic and Wegovy
In unadjusted analyses, the risk of all-cause mortality and recurrence did not differ significantly between GLP-1RA and SGLT2 inhibitor use, although adjusted models suggested lower hazards with GLP-1RA use
This shift opens a meaningful growth opportunity for CPG manufacturers ready to reframe indulgence as functional. The Food Institute Podcast At SIAL Canada 2026 in Montreal, Food Institute VP of Content and Insights Chris Campbell sat down with Mathieu Brisson, Global Sales Lead at Prestige Maple , to discuss how the company is transforming maple products for a rapidly evolving global food and beverage market.
After 8 weeks, there were no significant differences between groups in change of muscle strength
Lassen Sie uns ber Ihr Projekt sprechen Ihr Ansprechpartner: Armin Spinar